Incyte INCY suffered a setback in its ongoing mid-stage study on MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU).

Incyte Corp.'s ($INCY) stock plunged over 13% on Tuesday after the biopharma company announced setbacks with two drugs ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...

The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

If you're being treated for hives, your physician will want to hear what you think about your treatment. Is it working? Are your symptoms improving, staying the same, or getting worse? You may be ...